In today’s ACT Brief, we examine how large de-identified datasets are reshaping trial design and site strategy, why global ...
Understand where real-world evidence most effectively complements or substitutes traditional trial data, from post-market surveillance and label expansion to challenging areas such as rare disease ...
Explore how large-scale, de-identified real-world datasets enable more representative trial design, improve site selection, ...
In today’s ACT Brief, we look at how FDA policy is accelerating the use of de-identified real-world evidence in clinical ...
In today’s ACT Brief, we examine why life sciences companies are maintaining DEI commitments amid political pressure, what’s ...
In today’s ACT Brief, we look at why durable signal closure is emerging as a defining metric in risk-based quality management ...
Pharma is understandably risk-averse, and many companies remain in pilot mode, running small experiments that never scale.
In today’s ACT Brief, we look at efforts to address sex-based evidence gaps in Parkinson’s disease research, why ...
In today’s ACT Brief, we look at how global clinical development is evolving through decentralized models and emerging ...
Meeting sites where they are—within their systems, workflows, and technology—is something we’re deeply interested in ...
When we think about where AI can help, it’s about reducing administrative burden. Tools like Smart Draft help streamline ...
A look at how efficiency, access, platformization, AI, non-traditional players, and regulatory recovery are expected to reshape clinical operations in 2026. Efficiency, redefined: Faster trials ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results